US 12,030,901 B2
Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
Tom G. Driver, Chicago, IL (US); Roberto F. Machado, Carmel, IN (US); Naijing Su, Newark, DE (US); Xinyu Guan, Chicago, IL (US); Wrickban Mazumdar, Chicago, IL (US); Kira Ratia, Chicago, IL (US); Jason Ralph Hickok, Chicago, IL (US); and Angelia Denise Lockett, Indianapolis, IN (US)
Assigned to THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed by THE TRUSTEES OF INDIANA UNIVERSITY, Indianapolis, IN (US); and THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
Filed on Nov. 16, 2022, as Appl. No. 18/056,089.
Application 18/056,089 is a division of application No. 16/967,279, granted, now 11,584,766, previously published as PCT/US2019/016684, filed on Feb. 5, 2019.
Claims priority of provisional application 62/626,188, filed on Feb. 5, 2018.
Prior Publication US 2023/0124268 A1, Apr. 20, 2023
Int. Cl. C07F 7/08 (2006.01); C07D 401/12 (2006.01); C07D 491/056 (2006.01)
CPC C07F 7/0816 (2013.01) [C07D 401/12 (2013.01); C07D 491/056 (2013.01)] 20 Claims
 
1. A compound of Formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
T is SiR1R2;
each of G, U, V, and W independently is CR4 or N, provided that at least three of G, U, V, and W are CR4;
x is 0, 1, or 2;
y is 0 or 1;
A is

OG Complex Work Unit Chemistry
Z is C═O;
each of R1 and R2 independently are C1-4alkyl or phenyl;
R3 is H, C1-4alkyl, or aryl;
each R4 independently is H, halo, C1-4alkyl, OH, OC1-4alkyl, OBn, O(C═O)(CH2)n(C═O)O(CH2CH2O)mC1-4alkyl, or O(C═O)O(CH2)n(C═O)(CH2CH2O)mH;
n is 1-4; and
m is 1-10.